Refractory Hepatocellular Carcinoma
6
2
3
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
16.7%
1 terminated out of 6 trials
0.0%
-86.5% vs benchmark
0%
0 trials in Phase 3/4
0%
1 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (6)
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Ligufalimab and Cadonilimab in Advanced Liver Cancers
JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer